Percutaneous ablative cryoimmunotherapy for micrometastaic abscopal effect: No complications

Area of Science:

• Oncology
• Immunotherapy
• Interventional Radiology

Background:

• Metastatic renal cell carcinoma (mRCC) shows some response to nivolumab (anti-PD-1 therapy).
• Programmed death 1 (PD-1) pathway inhibition can enhance anti-tumor T cell activity within the tumor microenvironment.
• Cryoablation debulks tumors while preserving intracellular antigens for immune recognition.

Purpose of the Study:

• To describe a novel approach combining CT-guided cryoablation with local nivolumab administration for mRCC.
• To evaluate the safety and preliminary efficacy of this combined modality in a single case.

Main Methods:

• Percutaneous cryoablation of a metastatic renal cell carcinoma lesion.
• Local administration of nivolumab during the cryoablation procedure.
• Follow-up PET/CT scan to assess treatment response and clinical outcome.

Main Results:

• One month post-procedure, PET scans showed reduced uptake in smaller bone metastases, with complete elimination of the smallest lesion.
• The largest bone lesion showed a slight decrease in size and a slight increase in uptake.
• The patient experienced significant pain relief, enabling independent ambulation.

Conclusions:

• Combining cryoablation with local nivolumab may offer a minimally invasive strategy for mRCC.
• This approach has the potential to augment systemic anti-tumor immune responses by preserving antigens and enhancing T cell activity.
• Further investigation is warranted to confirm the efficacy and broader applicability of this combined treatment modality.